Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
- Author
- Renate De Smedt (UGent) , Sofie Peirs (UGent) , Julie Morscio (UGent) , Filip Matthijssens (UGent) , Juliette Roels (UGent) , Lindy Reunes (UGent) , Béatrice Lintermans (UGent) , Steven Goossens (UGent) , Tim Lammens (UGent) , Nadine Van Roy (UGent) , Aurore Touzart, Silvia Jenni, Yi-Chien Tsai, Federica Lovisa, Lara Mussolin, Valentina Serafin, Filip Van Nieuwerburgh (UGent) , Dieter Deforce (UGent) , Anne Uyttebroeck, Thomas Tousseyn, Birgit Burkhardt, Wolfram Klapper, Barbara De Moerloose (UGent) , Yves Benoit (UGent) , Elizabeth Macintyre, Jean-Pierre Bourquin, Giuseppe Basso, Benedetta Accordi, Beat Bornhauser, Jules Meijerink, Peter Vandenberghe and Pieter Van Vlierberghe (UGent)
- Organization
- Keywords
- SMALL-MOLECULE INHIBITOR, PROTEIN-KINASES, GROWTH
Downloads
-
e17.full.pdf
- full text
- |
- open access
- |
- |
- 909.69 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8589108
- Chicago
- De Smedt, Renate, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Béatrice Lintermans, et al. 2018. “Pre-clinical Evaluation of Second Generation PIM Inhibitors for the Treatment of T-cell Acute Lymphoblastic Leukemia and Lymphoma.” Haematologica 104 (1): e17–e20.
- APA
- De Smedt, R., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., et al. (2018). Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. HAEMATOLOGICA, 104(1), e17–e20.
- Vancouver
- 1.De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, et al. Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. HAEMATOLOGICA. 2018;104(1):e17–e20.
- MLA
- De Smedt, Renate et al. “Pre-clinical Evaluation of Second Generation PIM Inhibitors for the Treatment of T-cell Acute Lymphoblastic Leukemia and Lymphoma.” HAEMATOLOGICA 104.1 (2018): e17–e20. Print.
@article{8589108,
author = {De Smedt, Renate and Peirs, Sofie and Morscio, Julie and Matthijssens, Filip and Roels, Juliette and Reunes, Lindy and Lintermans, B{\'e}atrice and Goossens, Steven and Lammens, Tim and Van Roy, Nadine and Touzart, Aurore and Jenni, Silvia and Tsai, Yi-Chien and Lovisa, Federica and Mussolin, Lara and Serafin, Valentina and Van Nieuwerburgh, Filip and Deforce, Dieter and Uyttebroeck, Anne and Tousseyn, Thomas and Burkhardt, Birgit and Klapper, Wolfram and De Moerloose, Barbara and Benoit, Yves and Macintyre, Elizabeth and Bourquin, Jean-Pierre and Basso, Giuseppe and Accordi, Benedetta and Bornhauser, Beat and Meijerink, Jules and Vandenberghe, Peter and Van Vlierberghe, Pieter},
issn = {0390-6078},
journal = {HAEMATOLOGICA},
language = {eng},
number = {1},
pages = {e17--e20},
title = {Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma},
url = {http://dx.doi.org/10.3324/haematol.2018.199257},
volume = {104},
year = {2018},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: